Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Replimune received a “Moderate Buy” consensus rating from 10 analysts, including six buys and one strong buy, with an average 12-month price target of $12.00.
• The stock opened at $12.87 and has risen substantially from its 52-week low of $1.50, while the company reported a quarterly loss of $0.72 per share, missing estimates by $0.03.
• Institutional investors own 92.53% of Replimune, while insiders have sold 79,124 shares worth about $1.04 million over the past 90 days; the company is developing oncolytic immunotherapies, led by candidate RP1.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten brokerages that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $12.00.

REPL has been the subject of several research analyst reports. Wolfe Research raised Replimune Group to an "outperform" rating in a research report on Tuesday, August 4th. JPMorgan Chase & Co. raised their target price on Replimune Group from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Wednesday, August 26th. Piper Sandler raised Replimune Group from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 31st. Weiss Ratings lowered Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, August 11th. Finally, Wedbush raised Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price objective for the company in a research report on Friday, August 7th.

Replimune Group Stock Down 0.7%

Replimune Group stock opened at $12.87 on Friday. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -4.09 and a beta of 0.94. The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. Replimune Group has a fifty-two week low of $1.50 and a fifty-two week high of $16.33. The firm has a fifty day moving average price of $12.66 and a two-hundred day moving average price of $8.96.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). As a group, analysts forecast that Replimune Group will post -2.81 earnings per share for the current year.

Insider Activity at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 39,341 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the completion of the sale, the chief executive officer directly owned 708,151 shares of the company's stock, valued at $9,184,718.47. This represents a 5.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the business's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,467.59. Following the transaction, the insider owned 224,215 shares in the company, valued at approximately $2,908,068.55. The trade was a 4.86% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 79,124 shares of company stock valued at $1,038,364 in the last 90 days. 5.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Replimune Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in REPL. Quantinno Capital Management LP lifted its position in Replimune Group by 782.7% in the first quarter. Quantinno Capital Management LP now owns 108,477 shares of the company's stock worth $830,000 after purchasing an additional 96,188 shares during the period. Montanova Capital LLC increased its holdings in Replimune Group by 4.0% in the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company's stock valued at $48,595,000 after buying an additional 168,000 shares during the period. Seven Fleet Capital Management LP bought a new stake in Replimune Group in the 1st quarter valued at $921,000. EcoR1 Capital LLC acquired a new position in shares of Replimune Group in the 1st quarter valued at $7,650,000. Finally, Deutsche Bank AG acquired a new position in shares of Replimune Group in the 2nd quarter valued at $857,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a biotechnology company focused on developing oncolytic immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company's approach is based on a proprietary platform that uses genetically engineered herpes simplex virus type 1 (HSV-1) to selectively replicate in tumors and deliver immune-activating payloads.

Replimune's lead product candidate is RP1, also known as vusolimogene oderparepvec, an investigational oncolytic immunotherapy being evaluated in clinical studies for solid tumors, including melanoma and cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.